Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...

In 2023, combined revenue for Zevtera and another drug, Cresemba, reached 150 million Swiss francs, or about $166 million. With antibiotic resistance on the rise, new drugs are needed to treat a range ...